- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Retrospective, Single centre
- Study aim: To evaluate the clinical outcomes of immunocompromised patients treated with nirmatrelvir/ritonavir and to assess the occurrence of drug-to-drug interactions and treatment-emergent adverse events in this population
- Number of participants enrolled: 110
- Study enrolling from to
- Study includes follow-up for 1 month
Study Data
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
External Links
Other information
Funders:
- European Regional Development Fund
- European Social Fund
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to